

B<sup>1</sup>  
conceded

entrapped bioactive agent; and administering to said animal an anti-inflammatory agent wherein said adverse physiological reaction is reduced.

B<sup>2</sup>

23. (Amended) A method of treating an animal with a bioactive agent comprising administering to said animal a composition comprising:

- (i) a liposome; and
- (ii) an anti-inflammatory agent;

wherein said liposome composition induces an adverse physiological reaction in said animal in the absence of an anti-inflammatory agent; thereby reducing said adverse physiological reaction.

B<sup>3</sup>

25. (Amended) A composition comprising a liposome in combination with an anti-inflammatory agent not contained in the liposome.

B<sup>4</sup>

29. (Amended) A composition comprising (i) a liposome composition, and (ii) an anti-inflammatory agent, wherein said liposome composition comprises a liposome encapsulated contrast agent.

B<sup>5</sup>

33. (Amended) The composition of claim 29 wherein the liposome comprises a lipid bilayer having a lipid and a surface agent-modified molecule which comprises an anchor and a surface modifying agent and wherein the liposome has an average diameter of from at least about 220 nm to about 5000 nm.

36. (Amended) The composition of claim 33, wherein the concentration of surface agent modified molecule in the bilayer is at least about 2 mole percent.

*B4*  
37. (Amended) The composition of claim 33, wherein the surface modifying agent is a dicarboxylic acid, a monocarboxylic acid or a sulfolipid.

38. (Amended) The composition of claim 33, wherein the surface modifying agent is a dicarboxylic acid.

41. (Amended) The composition of claim 33, wherein the anchor is a phosphatidylethanolamine.

*B7*  
42. (Amended) The composition of claim 41, wherein the phosphatidylethanolamine is dipalmitoyl phosphatidylethanolamine.

43. (Amended) The composition of claim 25, wherein said liposome comprises a lipid bilayer having a lipid and a surface modified molecule, said surface agent modified molecule comprising a phospholipid anchor having a glycerol backbone and a spacer group, and wherein said spacer group comprises a functional group capable of attaching to the glycerol backbone and a functional group capable of attaching to the phosphate group of the phospholipid anchor

Please add the following new claims 45-55:

--45. A pharmaceutical composition comprising:

- (i) a bioactive agent containing liposome; and
- (ii) an anti-inflammatory agent.

*NE*  
46. The pharmaceutical composition of claim 45, wherein the bioactive agent is a contrast agent.

47. The pharmaceutical composition of claim 45, wherein the anti-inflammatory agent is indomethacin.

48. The pharmaceutical composition of claim 45, wherein the liposome comprises a lipid bilayer having a lipid and a surface agent-modified molecule which comprises an anchor and a surface modifying agent, and wherein the liposome has an average diameter of from at least about 220 nm to about 5000 nm.

49. The pharmaceutical composition of claim 48, wherein the liposome has an average diameter of from about 400 nm to about 1000 nm.

50. The pharmaceutical composition of claim 48, wherein the surface modifying agent is a dicarboxylic acid, a monocarboxylic acid or a sulfolipid.

51. The pharmaceutical composition of claim 48, wherein the surface modifying agent is a dicarboxylic acid.

52. The pharmaceutical composition of claim 48, wherein the surface agent modified molecule comprises a phospholipid anchor having a glycerol backbone and a spacer group, and wherein said spacer group comprises a functional group capable of attaching to the glycerol backbone and a functional group capable of attaching to the phosphate group of the phospholipid anchor.

53. The composition of claim 25, wherein the liposome comprises a bioactive agent.

54. A composition comprising a liposome encapsulated contrast agent, wherein said liposome comprises a lipid bilayer having a lipid and a surface agent-modified molecule which comprises an anchor and a surface modifying agent, and wherein said liposome has an average diameter of from at least about 220 nm to about 5000 nm.

55. The method of claim 18, wherein said anti-inflammatory agent is administered to said animal prior to administration of said liposome composition.--